Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Cash & Current Investments for 8 consecutive years, with $443.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Current Investments fell 8.7% year-over-year to $443.5 million; the TTM figure through May 2026 stood at $443.5 million (down 8.7% YoY), while the FY2025 annual figure was $592.9 million, down 2.73% from the prior year.
• Cash & Current Investments retreated to $443.5 million in Q2 2026 per NRIX's latest filing, from $540.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $609.6 million in Q4 2024 and bottomed at $244.0 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $394.7 million across 5 years, with a median of $386.7 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Current Investments slipped 24.86% — and 2025, when it surged 125.29%.
• Nurix Therapeutics' Cash & Current Investments stood at $309.1 million in 2022, then retreated by 6.87% to $287.9 million in 2023, then surged by 111.73% to $609.6 million in 2024, then decreased by 2.73% to $592.9 million in 2025, then retreated by 25.2% to $443.5 million in 2026.
• Business Quant data shows NRIX's Cash & Current Investments at $443.5 million in Q2 2026, $540.7 million in Q1 2026, and $592.9 million in Q4 2025.